TD Cowen analyst Charles Rhyee raised the firm’s price target on GoodRx (GDRX) to $4 from $3 and keeps a Buy rating on the shares. The firm said the company showed an encouraging quarter, with Pharma Direct driving a consolidated beat/raise on revenues and EBITDA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Analyst Maintains Buy on GoodRx as High-Value Segments Gain Traction; Price Target Kept at $3.50
- GoodRx Earnings Call Highlights Pharma Direct Momentum
- GoodRx price target raised to $3.50 from $2.50 at Goldman Sachs
- Notable companies reporting after market close
- GoodRx reports Q1 adjusted EPS 7c, consensus 7c